Positions

Overview

  • Dr. Antony is Professor of Medicine at the University of Alabama at Birmingham (UAB). Dr. Antony's medical training began at Christian Medical College in Ludhiana, India. Following medical school, Dr. Antony progressed to an internship and residency at New York's Kingsbrook Jewish Medical Center. Following her Pulmonary and Critical Care Medicine Fellowship training in the University of Colorado's School of Medicine, Dr. Antony worked in Pulmonary Medicine at the University of Colorado Health Sciences Center, the Indiana University School of Medicine, and the University of Florida before beginning her work at UAB in 2010.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Erratum: Microanatomic Distribution of Myeloid Heme Oxygenase-1 Protects against Free Radical-Mediated Immunopathology in Human Tuberculosis (Cell Reports (2018) 25(7) (1938–1952.e5), (S2211124718316772), (10.1016/j.celrep.2018.10.073)) 2019
    2019 Vimentin intermediate filament assembly regulates fibroblast invasion in fibrogenic lung injury 2019
    2018 Unique Lipid Signatures of Extracellular Vesicles from the Airways of Asthmatics 2018
    2018 Macrophage Rac2 is required to reduce the severity of cigarette smoke-induced pneumonia 2018
    2018 Microanatomic Distribution of Myeloid Heme Oxygenase-1 Protects against Free Radical-Mediated Immunopathology in Human Tuberculosis 2018
    2018 Exosomal transfer of mitochondria from airway myeloid-derived regulatory cells to T cells 2018
    2018 Cellular senescence in chronic obstructive pulmonary disease: Multifaceted and multifunctional 2018
    2018 Is personalized medicine a realistic goal in idiopathic pulmonary fibrosis? 2018
    2018 Cutaneous exposure to lewisite causes acute kidney injury by invoking dna damage and autophagic response 2018
    2018 Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients 2018
    2017 Home monitoring of patients with cystic fibrosis to identify and treat acute pulmonary exacerbations eICE study results 2017
    2017 Serpine 1 induces alveolar type II cell senescence through activating p53-p21-Rb pathway in fibrotic lung disease 2017
    2017 Autoimmunity to vimentin is associated with outcomes of patients with idiopathic pulmonary fibrosis 2017
    2017 3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs 2017
    2017 MIR-34a inhibits lung fibrosis by inducing lung fibroblast senescence 2017
    2017 3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs. 2017
    2017 Low-dose cadmium exposure induces peribronchiolar fibrosis through site-specific phosphorylation of vimentin 2017
    2016 National institute of environmental health sciences: 50 years of advancing science and improving lung health 2016
    2016 Mechanosensing by the α 6-integrin confers an invasive fibroblast phenotype and mediates lung fibrosis 2016
    2016 Matrix remodeling in pulmonary fibrosis and emphysema 2016
    2016 Attenuated heme oxygenase-1 responses predispose the elderly to pulmonary nontuberculous mycobacterial infections 2016
    2016 Novel mechanisms for the antifibrotic action of nintedanib 2016
    2015 Noninvasive imaging of experimental lung fibrosis 2015
    2015 Heme oxygenase-1 protects Corexit 9500ainduced respiratory epithelial injury across species 2015
    2015 Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial 2015
    2015 SMAD-independent down-regulation of caveolin-1 by TGF-β: Effects on proliferation and survival of myofibroblasts 2015
    2015 Blue Journal Conference: Aging and susceptibility to lung disease 2015
    2015 Heme oxygenase-1-mediated autophagy protects against pulmonary endothelial cell death and development of emphysema in cadmium-treated mice 2015
    2015 Plasminogen activator inhibitor 1, fibroblast apoptosis resistance, and aging-related susceptibility to lung fibrosis 2015
    2015 Pleural mesothelial cells in pleural and lung diseases 2015
    2014 Therapeutic targeting of Src kinase in myofibroblast differentiation and pulmonary fibrosis 2014
    2014 The effect of biomass fuel exposure on the prevalence of asthma in adults in India - Review of current evidence 2014
    2014 The pleural mesothelium in development and disease 2014
    2014 Wilms' tumor 1 (Wt1) regulates pleural mesothelial cell plasticity and transition into myofibroblasts in idiopathic pulmonary fibrosis 2014
    2013 MiR-145 regulates myofibroblast differentiation and lung fibrosis 2013
    2013 Pleural mesothelial cell differentiation and invasion in fibrogenic lung injury 2013
    2012 Heme oxygenase-1 promotes granuloma development and protects against dissemination of mycobacteria 2012
    2012 Parenchymal trafficking of pleural mesothelial cells in idiopathic pulmonary fibrosis 2012
    2011 A Trojan horse strategy to deliver amikacin to mycobacterial granulomas [1] 2011
    2011 New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis 2011
    2011 Silencing receptor EphA2 induces apoptosis and attenuates tumor growth in malignant mesothelioma. 2011
    2010 Targeted delivery of amikacin into granuloma 2010
    2009 Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to TGF-β1 in vitro 2009
    2009 Erythromycin improves gastric emptying half-time in adult cystic fibrosis patients with gastroparesis 2009
    2008 Innate immune responses in murine pleural mesothelial cells: Toll-like receptor-2 dependent induction of β-defensin-2 by staphylococcal peptidoglycan 2008
    2008 Thioredoxin as a biomarker for graft rejection in lung transplant recipients 2008
    2008 Pathophysiology of the pleura 2008
    2007 Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM) 2007
    2007 Bacterial induction of early response genes and activation of proapoptotic factors in pleural mesothelial cells 2007
    2007 Pleural effusions: How to confirm the cause - And manage effectively 2007
    2007 Induction of cell cycle arrest and apoptosis by BCG infection in cultured human bronchial airway epithelial cells 2007
    2007 Advances in pleural disease 2007
    2007 Erratum: "Talc mediates angiostasis in malignant pleural effusions via endostatin induction" (European Respiratory Journal (2007) vol. 29 (761-769)) 2007
    2007 Talc mediates angiostasis in malignant pleural effusions via endostatin induction 2007
    2007 Cyclic stretch induces PlGF expression in bronchial airway epithelial cells via nitric oxide release 2007
    2006 Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells 2006
    2006 Pleural Fibrosis 2006
    2005 Involvement of calpain-calpastatin in cigarette smoke-induced inhibition of lung endothelial nitric oxide synthase 2005
    2005 Respiratory system responsiveness in rabbits in vivo is reduced by prolonged continuous positive airway pressure 2005
    2005 The mysterious pulmonary brush cell: A cell in search of a function 2005
    2004 Primum non nocere and malignant pleural effusions 2004
    2004 RSV causes HIF-1α stabilization via NO release in primary bronchial epithelial cells 2004
    2004 Th2 cytokines IL-4 and IL-13 downregulate paxillin expression in bronchial airway epithelial cells 2004
    2004 Pathogenesis of pleural infection 2004
    2004 Respiratory syncytial virus causes increased bronchial epithelial permeability 2004
    2004 Talc pleurodesis: Basic fibroblast growth factor mediates pleural fibrosis 2004
    2003 Mycobacteria induces pleural mesothelial permeability by down-regulating β-catenin expression 2003
    2003 Defensive role of pleural mesothelial cell sialomucins in tumor metastasis 2003
    2003 Immunological mechanisms in pleural disease 2003
    2003 Pleural Mesothelial Cell (PMC) Defense Mechanisms Against Malignancy 2003
    2003 Pleural mesothelial cells modulate polymorphonuclear leukocyte apoptosis in empyema 2003
    2002 Adherence of Ovarian Cancer Cells Induces Pleural Mesothelial Cell (PMC) Permeability 2002
    2002 Low Molecular Weight Hyaluronan Induces Malignant Mesothelioma Cell (MMC) Proliferation and Haptotaxis: Role of CD44 Receptor in MMC Proliferation and Haptotaxis 2002
    2002 Fibrinolysis in the pleural space. Breaking the bonds that bind 2002
    2002 Drawing the line: Differentiating transudates from exudates 2002
    2002 Induction of MCP-1 expression in airway epithelial cells: Role of CCR2 receptor in airway epithelial injury 2002
    2002 Inflammatory cytokines mediate C-C (monocyte chemotactic protein 1) and C-X-C (interleukin 8) chemokine expression in human pleural fibroblasts 2002
    2002 When should decortication be done in patients with pleural disease? 2002
    2001 Bacterial induction of pleural mesothelial monolayer barrier dysfunction 2001
    2001 Management of malignant pleural effusions 2001
    2001 Bacterial induction of pleural mesothelial monolayer barrier dysfunction. 2001
    2001 Polar production of interleukin-8 by mesothelial cells promotes the transmesothelial migration of neutrophils: Role of intercellular adhesion molecule-1 2001
    2001 Pleural effusions: The workup and treatment 2001
    2000 Pleural effusions: How to interpret the signs 2000
    2000 Induction of acute pleural inflammation by Staphylococcus aureus. I. Cd4+ T cells play a critical role in experimental empyema 2000
    2000 MCP-1 in pleural injury: CCR2 mediates haptotaxis of pleural mesothelial cells 2000
    2000 MCP-1 in pleural injury: CCR2 mediates haptotaxis of pleural mesothelial cells. 2000
    2000 Talc induces apoptosis in human malignant mesothelioma cells in vitro. 2000
    2000 Management of malignant pleural effusions 2000
    2000 Talc induces apoptosis in human malignant mesothelioma cells in vitro 2000
    1999 Inhibition of interleukin-8 reduces human malignant pleural mesothelioma propagation in nude mouse model 1999
    1999 Mycobacterium-induced transmesothelial migration of monocytes into pleural space: Role of intercellular adhesion molecule-1 in tuberculous pleurisy 1999
    1999 Helper T cell type 1 and 2 cytokines regulate C-C chemokine expression in mouse pleural mesothelial cells. 1999
    1999 Pathophysiology of pleural space infections 1999
    1999 Interleukin 8: An autocrine growth factor for malignant mesothelioma 1999
    1999 Helper T cell type 1 and 2 cytokines regulate C-C chemokine expression in mouse pleural mesothelial cells 1999
    1999 Pathogenesis of malignant pleural effusions and talc pleurodesis 1999
    1998 Mycobacterium-mediated chemokine expression in pleural mesothelial cells: role of C-C chemokines in tuberculous pleurisy. 1998
    1998 Drug-induced pleural disease 1998
    1998 Macrophage inflammatory protein-1α C-C chemokine in parapneumonic pleural effusions 1998
    1998 Preface 1998
    1998 Talc-induced expression of C-C and C-X-C chemokines and intercellular adhesion molecule-1 in mesothelial cells 1998
    1997 Pleurodesis: State of the art 1997
    1997 Immunobiology of pleural inflammation: Potential implications for pathogenesis, diagnosis and therapy 1997
    1997 Pleurodesis: State of the art 1997
    1996 Thoracoscopy: The pumonologist's role 1996
    1996 Angiogenesis in mesotheliomas. Role of mesothelial cell derived IL-8. 1996
    1996 Adenosine deaminase isoenzymes and pleural tuberculosis. 1996
    1996 Mechanism of talc induced pleurodesis 1996
    1995 Pleural mesothelial cell expression of C-C (monocyte chemotactic peptide) and C-X-C (interleukin 8) chemokines. 1995
    1995 Testing the waters: Differentiating transudates from exudates 1995
    1995 Thoracoscopy: The pulmonologist's role 1995
    1994 The immunopathology of chemotactic cytokines: The role of interleukin-8 and monocyte chemoattractant protein-1 1994
    1994 Daidzin, an Antioxidant Isoflavonoid, Decreases Blood Alcohol Levels and Shortens Sleep Time Induced by Ethanol Intoxication 1994
    1994 Mesothelial cell modulation of pleural repair: Thrombin stimulated mesothelial cells release prostaglandin E2 1994
    1993 Alcohol‐Induced Inhibition of Alveolar Macrophage Oxidant Release in Vivo and in Vitro 1993
    1993 Recruitment of inflammatory cells to the pleural space: Chemotactic cytokines, IL-8, and monocyte chemotactic peptide-1 in human pleural fluids 1993
    1992 NHLBI workshop summaries. Pleural cell biology in health and disease. 1992
    1992 Mechanism of tetracycline-hydrochloride-induced pleurodesis: Tetracycline- hydrochloride-stimulated mesothelial cells produce a growth-factor-like activity for fibroblasts 1992
    1992 Mesothelial cell response to pleural injury: thrombin-induced proliferation and chemotaxis of rat pleural mesothelial cells. 1992
    1991 Alveolar cell population in HIV infected patients 1991
    1989 Cystic fibrosis tracheobronchial effluent stimulates proliferation of lung fibroblasts in vitro 1989
    1989 Mechanisms of pleural fibrosis in empyema. Pleural macrophage-mediated inhibition of fibroblast proliferation 1989
    1989 Pleural mesothelial cells stimulated by asbestos release chemotactic activity for neutrophils in vitro 1989
    1988 Polymorphonuclear leukocyte cytoplasts mediate acute lung injury 1988
    1988 Stimulation of cAMP accumulation and superoxide production in human neutrophils and monocytes 1988
    1987 Pleural tuberculosis 1987
    1987 Pleurodesis--testing the waters. 1987
    1985 Bacillus Calmette-Guerin-stimulated neutrophils release chemotaxis for monocytes in rabbit pleural spaces and in vitro 1985
    1984 Pathogenesis of pleural plaques. Relationship of early cellular response and pathology 1984
    1983 Dimethyl sulfoxide inhibits phagocyte influx into infected pleural spaces and phagocyte locomotion in vitro 1983
    1983 The contribution of leukocytes and bacteria to the low pH of empyema fluid 1983
    1983 Inflammatory responses in experimental tuberculosis pleurisy 1983
    1983 The pathogenesis of the low pleural fluid pH in esophageal rupture 1983
    1983 Lung repair and granuloma formation. Tubercle bacilli stimulated neutrophils release chemotactic factors for monocytes. 1983
    1983 EFFECT OF DIMETHYL SULFOXIDE ON CHEMOTAXIS OF PHAGOCYTIC CELLS 1983
    1983 Lung repair and granuloma formation. Tubercle bacilli stimulated neutrophils release chemotactic factors for monocytes 1983
    1983 Lupus pleuritis. Clinical features and pleural fluid characteristics with special reference to pleural fluid antinuclear antibodies 1983
    1983 The pleuropulmonary manifestations of the postcardiac injury syndrome 1983
    1981 Empyema after internal jugular catheterisation in rheumatoid arthritis 1981

    Chapter

    Year Title Altmetric
    2006 Pleural Effusions: Malignant Pleural Effusions.  372-379. 2006
    2003 Chemokines in pleural disorders.  325-339. 2003

    Research Overview

  • Dr. Antony’s research is focused on environmental and translational medicine, cystic fibrosis, pleural disease, and lung injury. Active studies involve work in the development of novel anti-fibrotic therapies, disease-relevant animal models of non-resolving fibrosis, the role of HO-1 in protection against bromine-induced lung injury/fibrosis, and the infrastructure needed to support cystic fibrosis clinical trials.
  • Principal Investigator On

  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease - Core C: Clinical Core  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2018 - 2023
  • Environmental Cadmium and COPD  awarded by National Institute of Environmental Health Sciences/NIH/DHHS 2018 - 2023
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2018 - 2020
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2018 - 2020
  • Award for a Physical Therapist  awarded by Cystic Fibrosis Foundation 2017 - 2019
  • Physical Therapist - UAB Adult CF Clinic  awarded by Cystic Fibrosis Foundation 2016 - 2019
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease: Core C - Clinical Core  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2013 - 2018
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease: Project 1 - Activation of the Pleural Mesothelium in IPF  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2013 - 2018
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research (Adult)  awarded by Cystic Fibrosis Foundation 2011 - 2017
  • Award for a Mental Health Coordinator  awarded by Cystic Fibrosis Foundation 2017
  • Early Intervention in Pulmonary Exacerbation  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2012 - 2016
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC. 2012 - 2016
  • TDN Additional Research Coordinator (ARC)  awarded by Cystic Fibrosis Foundation 2014 - 2015
  • HO-1 and Granuloma Formation in TB Pleurisy  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2010 - 2012
  • Investigator On

  • UAB Research Center of Excellence in Arsenicals  awarded by National Institute of Environmental Health Sciences/NIH/DHHS 2018 - 2023
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2018 - 2023
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease - Project Three: Metabolic Regulation of Pro-Fibrotic Macrophages in Pulmonary Fibrosis  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2018 - 2023
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease - Project Two: Redox Regulation of Metabolic Reprogramming in Activated Myofibroblasts  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2018 - 2023
  • G551D Observational Study-Expanded to Additional Genotypes and Extended for Long Term Follow-Up (GOAL-e2)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2013 - 2020
  • Cigarette Smoke Impairs Innate Immunity in Alveolar Macrophages  awarded by PARKER B. FRANCIS FOUNDATION 2017 - 2020
  • Bromine Inhalation Induced Lung Injury: Novel Mechanisms and Treatment Strategies  awarded by National Institute of Environmental Health Sciences/NIH/DHHS 2015 - 2020
  • Myofibroblast Senescence in Pulmonary Fibrosis  awarded by National Institute on Aging/NIH/DHHS 2014 - 2019
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2013 - 2018
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease: Core B - Animal and Therapeutics Core  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2013 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2015
  • Translational Therapeutic Development Center  awarded by Cystic Fibrosis Foundation 2013 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2010 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2014
  • Private Grant  awarded by N30 PHARMACEUTICALS, LLC 2013 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2014
  • Private Grant  awarded by N30 PHARMACEUTICALS, LLC 2013
  • Full Name

  • Veena Antony